AP-02 is LNP-formulated composite siRNAs that work in concert to specifically downregulate the expression of the gene enconding MIR-2, an invadopodia-specific membrane receptor that regulates multiple signaling processes important for the invadopodial biogenesis and functions in invasive cancer cells. Antapodia Nanotherapeutics's POM/POC studies show that AP-02 is able to dose-dependently suppress the expression of total and cell-surface MIR-2 in invasive cancer cells (Figure 1), thereby inhibiting invadopodia formation and cell invasiveness (Figure 2). In a pancreatic cancer metastasis model, systemic administrations of AP-02 abolish distant metastasis and significantly lengthen survival (Figure 3). The company is now using PDX and syngeneic mouse tumor models to further substantiate the therapeutic potential of AP-02.

Figure 1.  AP-02 dose-dependently inhibits total (A) and cell-surface (B) MIR-2 expression in pancreatic cancer cells

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival.

Figure 2.  AP-02 abrogates invadopodia formation (A) and inhibits cancer cell invasiveness (B)

Figure 2.  Systemic administration of AP-01 abolishes breast cancer metastasis.

Figure 3.  Systemic AP-02 therapy inhibits pancreatic cancer aggressiveness and metastasis

(metastasis control rate: 92.7%)

Figure 3.  Combined local and systemic AP-01 treatment shrinks primary breast cancer and prevents pulmonary metastasis.
Copyright © Antapodia Nanotherapeutics, Inc. All Rights Reserved